Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Enterobacteriales Coresistant to Carbapenems and Polymyxins

EVALUATION OF CEFTAZIDIME ANTIMICROBIAL ACTIVITY IN INFECTIONS CAUSED BY BURNS

In vitro evaluation of ceftazidime antimicrobial activity in infections caused by burn and its comparison to the other antibiotics is presented. In vitro tests for susceptibility to ceftazidime and other antibiotics were carried out on 744 bacterial strains collected from burn infections. The results have shown that generally ceftazidime was more active against Pseudomollas aeruginosa an...

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam

evaluation of ceftazidime antimicrobial activity in infections caused by burns

in vitro evaluation of ceftazidime antimicrobial activity in infections caused by burn and its comparison to the other antibiotics is presented. in vitro tests for susceptibility to ceftazidime and other antibiotics were carried out on 744 bacterial strains collected from burn infections. the results have shown that generally ceftazidime was more active against pseudomollas aeruginosa and other...

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections

INTRODUCTION The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors. Ceftazidime-avibactam is one of t...

Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation.

Enterobacteriaceae are an important cause of infections, and the infection recurred weeks after finishing the antibiotic cycle, which led to another hospitalisation. For this reason, we decided to initiate treatment with the recent antibiespecially in immunocompromised patients. The recent appearance of carbapenemase-producing enterobacteriaceae otic ceftazidime–avibactam (C–A) for 2 weeks at a...